全文获取类型
收费全文 | 55188篇 |
免费 | 4011篇 |
国内免费 | 177篇 |
专业分类
耳鼻咽喉 | 510篇 |
儿科学 | 1484篇 |
妇产科学 | 1222篇 |
基础医学 | 8081篇 |
口腔科学 | 820篇 |
临床医学 | 7007篇 |
内科学 | 10465篇 |
皮肤病学 | 932篇 |
神经病学 | 6047篇 |
特种医学 | 1508篇 |
外科学 | 5998篇 |
综合类 | 598篇 |
现状与发展 | 1篇 |
一般理论 | 53篇 |
预防医学 | 5555篇 |
眼科学 | 1036篇 |
药学 | 3741篇 |
1篇 | |
中国医学 | 88篇 |
肿瘤学 | 4229篇 |
出版年
2023年 | 369篇 |
2022年 | 587篇 |
2021年 | 1259篇 |
2020年 | 802篇 |
2019年 | 1306篇 |
2018年 | 1487篇 |
2017年 | 1154篇 |
2016年 | 1267篇 |
2015年 | 1409篇 |
2014年 | 1933篇 |
2013年 | 2643篇 |
2012年 | 4062篇 |
2011年 | 4194篇 |
2010年 | 2303篇 |
2009年 | 2104篇 |
2008年 | 3569篇 |
2007年 | 3822篇 |
2006年 | 3587篇 |
2005年 | 3711篇 |
2004年 | 3314篇 |
2003年 | 3130篇 |
2002年 | 2990篇 |
2001年 | 465篇 |
2000年 | 342篇 |
1999年 | 536篇 |
1998年 | 626篇 |
1997年 | 564篇 |
1996年 | 411篇 |
1995年 | 409篇 |
1994年 | 359篇 |
1993年 | 350篇 |
1992年 | 264篇 |
1991年 | 232篇 |
1990年 | 218篇 |
1989年 | 235篇 |
1988年 | 244篇 |
1987年 | 183篇 |
1986年 | 199篇 |
1985年 | 175篇 |
1984年 | 219篇 |
1983年 | 215篇 |
1982年 | 206篇 |
1981年 | 213篇 |
1980年 | 212篇 |
1979年 | 109篇 |
1978年 | 113篇 |
1977年 | 125篇 |
1976年 | 93篇 |
1975年 | 73篇 |
1974年 | 94篇 |
排序方式: 共有10000条查询结果,搜索用时 0 毫秒
51.
Tobias Engelhorn Sophia Goerike Arnd Doerfler Christine Okorn Michael Forsting Gerd Heusch Rainer Schulz 《Journal of cerebral blood flow and metabolism》2004,24(4):467-474
The goal of the present study was to test the impact of administration time of the angiotensin II type 1-receptor blocker candesartan on cerebral blood flow (CBF), infarct size, and neuroscore in transient cerebral ischemia. Therefore, 1-hour middle cerebral artery occlusion (MCAO) was followed by reperfusion. Rats received 0.5-mg/kg candesartan intravenously 2 hours before MCAO (pretreatment), 24 hours after MCAO, every 24 hours after MCAO, or 2 hours before and every 24 hours after MCAO. Infarct size (mm3) and a neuroscore at day 7 were compared with controls. CBF was quantified by radiolabeled microspheres and laser-Doppler flowmetry. Compared with controls (95 +/- 8), infarct size in candesartan-treated groups was smaller (59 +/- 5, 68 +/- 10, 28 +/- 3, and 15 +/- 3, respectively; P<0.05). Although there was no difference in neuroscore between pretreatment and controls (1.55 +/- 0.18, 1.80 +/- 0.13), other treatment regimens resulted in improved neuroscores (1.33 +/- 0.16, 1.11 +/- 0.11, 0.73 +/- 0.15; P<0.05). CBF in pretreated animals at 0.5 hours after MCAO was significantly higher than in controls (0.58 +/- 0.09 mL x g(-1) x min(-1) and 44% +/- 7% of baseline compared with 0.49 +/- 0.06 mL x g(-1) x min(-1) and 37% +/- 6%, microspheres and laser-Doppler flowmetry; P<0.05). Thus, candesartan reduces infarct size even if administered only during reperfusion. Apart from pretreatment, other treatment regimens result in significantly improved neuroscores. In the acute phase of cerebral ischemia, candesartan increases CBF. 相似文献
52.
Ellen J Schlette L Jeffrey Medeiros Andre Goy Raymond Lai George Z Rassidakis 《Journal of clinical oncology》2004,22(9):1682-1688
PURPOSE: Survivin, a member of the inhibitor of apoptosis (IAP) family, is not detected in normal adult tissues but is overexpressed in various cancers, including some types of lymphoma. The frequency and prognostic significance of survivin expression in anaplastic large-cell lymphoma (ALCL) is unknown. Materials and METHODS: We assessed for survivin expression in 62 ALCL tumors (30 anaplastic lymphoma kinase [ALK]-positive and 32 ALK-negative) obtained before doxorubicin-based chemotherapy. Given that survivin is a target of the STAT3 signaling pathway and STAT3 is activated in ALCL, survivin expression was also correlated with STAT3 activation. RESULTS: Survivin was expressed in 34 tumors (55%) and did not correlate with ALK. A significant association between survivin expression and STAT3 activation was observed (P =.007, Fisher's exact test). For the ALK-positive group, the 5-year failure-free survival (FFS) was 34% for patients with survivin-positive ALCL compared with 100% for patients with survivin-negative ALCL (P =.009, log-rank test). For the ALK-negative group, the 5-year FFS was 46% for patients with survivin-positive tumors compared with 89% for patients with survivin-negative tumors (P =.03, log-rank test). Overall survival was similarly worse for patients with survivin-positive tumors in both the ALK-positive and ALK-negative groups. Furthermore, multivariate analysis confirmed the independent prognostic value of survivin expression, along with age older than 60 years and Ann Arbor stage III or IV. CONCLUSION: Survivin is expressed in approximately half of ALCL tumors and independently predicts unfavorable clinical outcome. Modulation of survivin expression or function may provide a novel target for experimental therapy in patients with ALCL. 相似文献
53.
54.
Emilie Balasse Gregory Gatouillat Dominique Patigny Marie Christine Andry Claudie Madoulet 《Vaccine》2009
Malignant melanoma causes significant health problems. The identification of tumour-associated antigens has led to novel approaches to increase T cell mediated anti-tumour immune response. Melan-A/MART-1 has been use as target antigen for several T cell based immunotherapeutic treatments. More recently, the critical role of CD4+ T cells in inducing and maintaining anti-tumour immunity has been increasingly recognized. In order to optimize tumour immunotherapy, greater efforts have been concentrated on the identification of tumour antigens presented by MHC class II molecules to CD4+ T cells. In a publication, Tiwari et al. (2004) [1] have identified by a computational approach the 15-mer amino-acid sequence 101–115 (PPAYEKLSAEQSPPP) of the Melan-A/MART-1 as a good target for a vigorous and safe immunotherapy. Therefore, we have investigated the in vivo anti-tumour activity of this peptide in a murine melanoma model. For the prophylactic treatment, 20 μg or 50 μg peptide was subcutaneously injected in mice once a week during 3 weeks before tumour induction. Treatment with 50 μg peptide significantly affected tumour development. Thus, our preliminary data demonstrate potential in vivo prophylactic activity of the 101–115 peptide-based vaccine to control melanoma growth. 相似文献
55.
Peter B. Arnold Chris A. Campbell George Rodeheaver Wyndell Merritt Raymond F. Morgan David B. Drake 《Hand (New York, N.Y.)》2009,4(3):302-307
The purpose of this study was to demonstrate that perivascularly applied botulinum toxin-A (BTX) increases the diameter of
treated blood vessels in a rat femoral vessel exposure model. Six adult Sprague–Dawley rats were used and bilateral femoral
artery and vein exposures were performed. Five units of BTX were applied to the experimental side and an equal volume of sterile
saline was applied to the control side. Digital images of the vessels were obtained at the following time points: pretreatment,
immediately posttreatment, and postoperative days (POD) 1, 14, and 28. Vessel diameters were equivalent at baseline and immediately
following application of BTX and saline. The BTX artery was significantly larger than the control artery on POD 1 and 14.
The BTX treated artery was significantly larger than all other vessels on POD 14 (p < 0.05) as well as all prior time points (p < 0.01). Direct perivascular application of BTX increases the diameter of rat femoral vessels as early as POD 1. The affect
is most robust on POD 14 where the artery was significantly larger than all other vessels at all time points. It is likely
that the increased diameter of blood vessels results in an increased blood flow across the area of dilation. Such an increase
in flow may serve to improve end-organ perfusion in microvascular procedures. 相似文献
56.
Mats Bergstrom Azita Monazzam Pasha Razifar Susan Ide Raymond Josephsson Bengt Langstrom 《Journal of nuclear medicine》2008,49(7):1204-1210
For a PET agent to be successful as a biomarker in early clinical trials of new anticancer agents, some conditions need to be fulfilled: the selected tracer should show a response that is related to the antitumoral effects, the quantitative value of this response should be interpretable to the antitumoral action, and the timing of the PET scan should be optimized to action of the drug. These conditions are not necessarily known at the start of a drug-development program and need to be explored. We proposed a translational imaging activity in which experiments in spheroids and later in xenografts are coupled to modeling of growth inhibition and to the related changes in the kinetics of PET tracers and other biomarkers. In addition, we demonstrated how this information can be used for planning clinical trials. METHODS: The first part of this concept is illustrated in a spheroid model with BT474 breast cancer cells treated with the heat shock protein 90 (Hsp90) inhibitor NVP-AUY922. The growth-inhibitory effect after a pulse treatment with the drug was measured with digital image analysis to determine effects on volume with high accuracy. The growth-inhibitory effect was described mathematically by a combined E(max) and time course model fitted to the data. The model was then used to simulate a once-per-week treatment; in these experiments the uptake of the PET tracers (18)F-FDG and 3'-deoxy-3'-(18)F-fluorothymidine ((18)F-FLT) was determined at different doses and different time points. RESULTS: A drug exposure of 2 h followed by washout of the drug from the culture medium generated growth inhibition that was maximal at the earliest time point of 1 d and decreased exponentially with time during 10-12 d. The uptake of (18)F-FDG per viable tumor volume was minimally affected by the treatment, whereas the (18)F-FLT uptake decreased in correlation with the growth inhibition. CONCLUSION: The study suggests a prolonged action of the Hsp90 inhibitor that supports a once-per-week schedule. (18)F-FLT is a suitable tracer for the monitoring of effect, and the (18)F-FLT PET study might be performed within 3 d after dosing. 相似文献
57.
58.
RGD-based strategies for selective delivery of therapeutics and imaging agents to the tumour vasculature 总被引:12,自引:0,他引:12
Kai Temming Raymond M. Schiffelers Grietje Molema Robbert J. Kok 《Drug Resistance Updates》2005,8(6):381-402
During the past decade, RGD-peptides have become a popular tool for the targeting of drugs and imaging agents to alphavbeta3-integrin expressing tumour vasculature. RGD-peptides have been introduced by recombinant means into therapeutic proteins and viruses. Chemical means have been applied to couple RGD-peptides and RGD-mimetics to liposomes, polymers, peptides, small molecule drugs and radiotracers. Some of these products show impressive results in preclinical animal models and a RGD targeted radiotracer has already successfully been tested in humans for the visualization of alphavbeta3-integrin, which demonstrates the feasibility of this approach. This review will summarize the structural requirements for RGD-peptides and RGD-mimetics as ligands for alphavbeta3. We will show how they have been introduced in the various types of constructs by chemical and recombinant techniques. The importance of multivalent RGD-constructs for high affinity binding and internalization will be highlighted. Furthermore the in vitro and in vivo efficacy of RGD-targeted therapeutics and diagnostics reported in recent years will be reviewed. 相似文献
59.
Raymond Edler David Wertheim Darrel Greenhill 《American journal of orthodontics and dentofacial orthopedics》2004,125(4):435-443
This study related clinical assessments of the severity of mandibular asymmetry with computerized measurements, obtained by digitizing mandibular outlines from standardized facial photographs. Four ratios were calculated: area (size), compactness (shape), perimeter (length of outline), and moment (center of area). When comparing clinical severity with computer assessment, significant correlations were observed; those for area and compactness were the highest. Sixteen patients subsequently underwent corrective surgery, and their ratios were used to relate the degree of improvement to the original severity of the asymmetry. The posttreatment ratios were also used to audit the outcome, comparing the patients' scores as a group with results previously obtained from patients with normal symmetry and mild asymmetry. Posttreatment outcomes were significantly different from the normal outline group but were comparable with outcomes of patients with mild mandibular asymmetry. The system provided a sensitive, noninvasive method of assessing treatment change and could be useful in providing an objective means of quantifying treatment outcomes. 相似文献
60.
Neal R. Barshes Timothy C. Lee Ian W. Udell Christine A. O'Mahoney Beth A. Carter Saul J. Karpen John A. Goss 《American journal of transplantation》2005,5(8):2047-2051
Split liver transplantation (SLT) benefits society by increasing the total number of transplants that can be performed, but it is yet unknown if a decreased post-transplant survival (in comparison to whole liver transplantation) would make participation in SLT less appealing to adult liver transplant candidates. A 20-item questionnaire was administered to 50 adult candidates to assess attitudes toward SLT and organ sharing. The overall attitudes of 60% of participants were classified as utilitarian (maximizing benefit to greatest number of candidates), while 26% were classified as self-preserving (maximizing individual benefit) and 14% were undecided. Ninety percent of participants would be willing to share even if expected survival was less than that of whole liver transplantation, and 69% felt that pediatric candidates should have priority over adult candidates. In conclusion, attitudes toward graft sharing and the possibility of compromised survival benefit are not barriers to SLT for most adult liver transplant candidates. 相似文献